CAS No.865-21-4,Vinblastine Suppliers

Products Categories

Pharmaceutical (89)
Plant Extract (25)
Others (16)
Reagent (12)
Organic Chemicals (9)
Basic Inorganic Chemicals (2)
Materials (2)

Basic Information

Molecular Structure:
CAS No.:	865-21-4
Name:	Vinblastine
Article Data:	5

Formula:	C₄₆H₅₈N₄O₉
Molecular Weight:	810.988
Synonyms:	Vinblastine(7CI);(+)-Vinblastine;1H-Indolizino[8,1-cd]carbazole-5-carboxylic acid,4-(acetyloxy)-3a-ethyl-9-[5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-,methyl ester, [3aR-[3aa,4b,5b,5ab,9(3R,5S,7R,9S),10bR,13aa]]-;Rozevin;VLB;Valban;Vinblastin;Vincaleucoblastin;Vincaleucoblastine;[3aR-[3aa,4b,5b,5ab,9(3R,5S,7R,9S),10bR,13aa]]-Methyl 4-(acetyloxy)-3a-ethyl-9-[5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-1H-indolizino[8,1-cd]carbazole-5-carboxylate;
EINECS:	212-734-0
Density:	1.37 g/cm³
Melting Point:	211 - 216oC
Boiling Point:	755.65°C (rough estimate)
Appearance:	POWDER
PSA:	154.10000
LogP:	3.93170

Total:112 Page 1 of 3 1 2 3 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 865-21-4

History

Vinblastine (865-21-4) was first isolated by Robert Noble and Charles Thomas Beer from the Madagascar periwinkle plant. Vinblastine's utility as a chemotherapeutic agent was first discovered when it was crushed into a tea. Consumption of the tea led to a decreased number of white blood cells; therefore, it was hypothesized that vinblastine might be effective against cancers of the white blood cells such as lymphoma.

Consensus Reports

NCI Carcinogenesis Studies (ipr); No Evidence: mouse CANCAR Cancer. 40 (1977),1935. ; (ipr); Clear Evidence: rat CANCAR Cancer. 40 (1977),1935. . EPA Genetic Toxicology Program.

Specification

The CAS registry number of Vinblastine is 865-21-4. Its EINECS registry number is 212-734-0. The systematic name is (2α,3α,4α,5β,19β)-vincaleukoblastine. In addition, the molecular formula is C₄₆H₅₈N₄O₉ and the molecular weight is 810.97. It is also called Vincaleukoblastine. What's more, it is a vinca alkaloid and a chemical analogue of vincristine.

Physical properties about this chemical are: (1)ACD/LogP: 4.18; (2)# of Rule of 5 Violations: 2; (3)ACD/LogD (pH 5.5): 1.73; (4)ACD/LogD (pH 7.4): 3.69; (5)ACD/BCF (pH 5.5): 3.16; (6)ACD/BCF (pH 7.4): 284.81; (7)ACD/KOC (pH 5.5): 16; (8)ACD/KOC (pH 7.4): 1440.47; (9)#H bond acceptors: 13; (10)#H bond donors: 3; (11)#Freely Rotating Bonds: 12; (12)Polar Surface Area: 121.24 Å²; (13)Index of Refraction: 1.671; (14)Molar Refractivity: 220.74 cm³; (15)Molar Volume: 590 cm³; (16)Polarizability: 87.5 ×10^-24cm³; (17)Surface Tension: 70.9 dyne/cm; (18)Density: 1.37 g/cm³.

Preparation of Vinblastine: it can be prepared by C₅₄H₆₃N₅O₁₄. This reaction will need reagent H₂, catalyst 10percent Pd/C and solvent methanol. The reaction time is 2 hours at reaction temperature of 25 °C. The yield is about 89%.

Vinblastine can be prepared by C54H63N5O14

Uses of Vinblastine: it can used to treat some kinds of cancer, including Hodgkin's lymphoma, non-small cell lung cancer, breast cancer, head and neck cancer, and testicular cancer. It is also used to treat Langerhan cell histiocytosis. In addition, it can be used to get C₄₆H₅₆ClFN₄O₈ and C₄₆H₅₆F₂N₄O₈. This reaction will need reagents HF, SbF₅ and CHCl₃.

Vinblastine can be used to get C46H56ClFN4O8 and C46H56F2N4O8

You can still convert the following datas into molecular structure:
(1)SMILES: O=C(OC)[C@]4(c2c(c1ccccc1n2)CCN3C[C@](O)(CC)C[C@H](C3)C4)c5c(OC)cc6c(c5)[C@@]89[C@@H](N6C)[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]7(/C=C\CN([C@@H]78)CC9)CC
(2)InChI: InChI=1/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1
(3)InChIKey: JXLYSJRDGCGARV-CFWMRBGOBT

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
human	TDLo	ocular	14ug/kg (0.014mg/kg)	SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE SENSE ORGANS AND SPECIAL SENSES: CONJUNCTIVE IRRITATION: EYE SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE	British Journal of Ophthalmology. Vol. 62, Pg. 97, 1978.
man	LDLo	intravenous	2319ug/kg/38W (2.319mg/kg)	CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION	Lancet. Vol. 2, Pg. 692, 1980.
man	TDLo	unreported	80ug/kg (0.08mg/kg)	BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE	Cancer Chemotherapy Reports. Vol. 50, Pg. 219, 1966.
mouse	LD10	subcutaneous	20mg/kg (20mg/kg)		European Journal of Cancer. Vol. 10, Pg. 667, 1974.
mouse	LD50	intraperitoneal	3120ug/kg (3.12mg/kg)	BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE IMMUNOLOGICAL INCLUDING ALLERGIC: DECREASED IMMUNE RESPONSE	Cancer Treatment Reports. Vol. 61, Pg. 103, 1977.
mouse	LD50	intravenous	15mg/kg (15mg/kg)		United States Patent Document. Vol. #4279915,
rat	LD50	intravenous	2mg/kg (2mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1467, 1970.